Jump to content


  • Posts

  • Joined

  • Last visited

Everything posted by drrc

  1. iinet are good, but bob seems problematic: http://forums.whirlpool.net.au/forum/?acti...;f=72&q=bob
  2. Apparently the Recession Cut Deeper Than We Thought. BBC/AP LONDON , UK (Mar 22) Suicide bombers in Britain are set to begin a three-day strike on Monday in a dispute over the number of virgins they are entitled to in the afterlife. Emergency talks with Al Qaeda have so far failed to produce an agreement. The unrest began last Tuesday when Al Qaeda announced that the number of virgins a suicide bomber would receive after his death will be cut by 25% this February from 72 to only 60. The rationale for the cut was the increase in recent years of the number of suicide bombings and a subsequent shortage of virgins in the afterlife. The suicide bombers' union, the British Organization of Occupational Martyrs (B.O.O.M.) responded with a statement that this was unacceptable to its members and immediately balloted for strike action. General Secretary Abdullah Amir told the press, "Our members are literally working themselves to death in the cause of Jihad. We don't ask for much in return but to be treated like this is like a kick in the teeth". Speaking from his shed in Tipton in the West Midlands in which he currently resides, Al Qaeda chief executive Osama bin Laden explained, "We sympathize with our workers concerns but Al Qaeda is simply not in a position to meet their demands. They are simply not accepting the realities of modern-day Jihad in a competitive marketplace. Thanks to Western depravity, there is now a chronic shortage of virgins in the afterlife. It’s a straight choice between reducing expenditure and laying people off. I don’t like cutting wages, but I’d hate to have to tell 3000 of my staff that they won’t be able to blow themselves up.†Spokespersons for the union in the North East of England, Ireland , Wales , and the entire Australian continent stated that the strike would not affect their operations as “There are no virgins in their areas anyway.†Apparently the drop in the number of suicide bombings has been put down to the emergence of that Scottish singing star, Susan Boyle – now that Muslims know what a virgin looks like they are not so keen on going to Paradise .
  3. http://news.smh.com.au/breaking-news-world...00519-vf0z.html
  4. http://www.skinandaging.com/content/skinti...arter-screening
  5. http://7thspace.com/headlines/343051/risk_...ence_study.html
  6. hi eb, cmv normally inhabits up to 80% of the adult population, but rarely causes a problem (ie latent). however in the immunocompromised (transplant/hiv etc etc), it can reactivate and commonly cause death. qft-cmv measures the person's immune response to cmv, and therefor whether or not they are vulnerable to reactivation and disease, and importantly, if they have enough cells to fight the infection successfully. there are other well established tests available to test for active infection, including culture and pcr. so the real advantage of this test is to see which of the immunocompromised are at risk of developing serious disease, and then target monitoring and treatment towards them. hope this helps. cheers!
  7. New Blood Test Successfully Predicts Risk of Infection in Transplant Recipients
  8. msy's website is pretty crap. this one is better at sorting through their mess: msy but readable
  9. Blood Tests Demonstrate Superior Accuracy in Diagnosing Tuberculosis, Finds CHEST Meta-Analysis VALENCIA, Calif., April 6 /PRNewswire/ -- New data from a meta-analysis of existing literature published today in CHEST, the official journal of the American College of Chest Physicians, demonstrate that Interferon Gamma Release Assays (IGRAs) are superior to the previous standard in diagnostics, the 100+-year-old tuberculin skin test (TST), for detecting confirmed active Tuberculosis (TB) disease. This was especially true when the IGRAs, both QuantiFERON®-TB Gold (QFT), which is manufactured by Cellestis Limited, as well as the T-SPOT®-TB (T-Spot), were administered in developed countries. In the United States (U.S.), TB remains a public health threat, with as many as 14 million Americans infected with TB bacteria. At any given time, members from this large pool of infected people can develop full-blown, highly contagious TB. This new meta-analysis provides further evidence supporting a new, scientifically-proven standard for detecting tuberculosis infection. "Tuberculosis remains a global public health threat and as such, should be regarded with a corresponding level of urgency," said lead study author Roland Diel, MD, MPH, Assistant Professor, Department of Pulmonary Medicine, Medical School (MHH) Hannover. "The study results support IGRAs as modern advances in diagnosing a very old disease that is just as significant today as it was in the 1700s." The authors critically reviewed and analyzed 124 studies investigating the commercial QFT and T-Spot blood tests and TST for sensitivity (the percentage of infected persons who return a positive test result) in confirmed active TB cases and specificity (the percentage of uninfected persons who return a negative test result) in individuals with no risk factors for infection. Researchers found that the newer blood tests provide significant improvements in sensitivity over TST. The authors reviewed studies from developed countries and found the TST had only 71.5 percent sensitivity compared with QFT at 84.5 percent and the T-Spot at 88.5 percent. In a country with a relatively low rate of TB disease, such as the U.S., specificity is more important because poor specificity leads to greater numbers of false positives. QFT is highly specific at 99.2 percent versus 86.3 percent for T-Spot. By comparison, TST specificity may be as low as 59 percent in persons who are BCG-vaccinated and only 97 percent in non-vaccinated populations. To highlight the importance of specificity in low prevalence settings, in testing 1,000 persons without TB, the TST would return between 30 and 410 false-positives, T-Spot would return 157 false-positive test results; QFT only eight. "In addition to aiding the prevention of future outbreaks, improved tuberculosis diagnostics reduce the costs associated with TB control," said Tony Radford, Chief Executive Officer, Cellestis Limited. "With QFT virtually eliminating false-positive readings that are common with TST, TB control and treatment can now be more accurately targeted to those persons who truly are infected, minimizing unnecessary further testing and treatment." Additional Meta-Analysis Results This new analysis was conducted to establish performance benchmarks, and to this end, only took into account work based on accepted "gold standards" of diagnostic confirmation of active TB disease. The analysis highlights an added benefit that IGRAs offer over TST -- built-in control for measuring immune status of persons tested. This reduces the risk of false-negative results in those with compromised immune systems. IGRAs flag such individuals with a result of "Indeterminate". The pooled rate for all populations of indeterminate results was low, 2.1 percent for the QFT and 3.8 percent for T-Spot. About Tuberculosis Tuberculosis (TB) is a contagious disease caused by a bacterium called Mycobacterium tuberculosis. TB bacteria usually attack the lungs, but can affect any part of the body such as the kidney, spine, and brain. If not treated properly, TB can be fatal. TB bacteria is spread through the air when a person with TB disease of the lungs or throat coughs, sneezes, speaks, or sings, which may lead people in close proximity to become infected. According to the World Health Organization, about one person dies of TB every 17 seconds, causing nearly 2 million deaths annually. TB continues to be a contagious scourge in developing countries, and with the world shrinking rapidly due to global migration, it is a major public health threat in developed nations as well, including the United States. Each infected person represents a potential yet preventable future outbreak. Convenient and trustworthy testing for TB infection is necessary in order to quickly identify the appropriate persons for treatment and thereby prevent its spread. About QuantiFERON®-TB Gold (QFT) QuantiFERON®-TB Gold (QFT) is a simple blood test that accurately identifies people infected with Mycobacterium tuberculosis, the causative agent of Tuberculosis (TB). As a modern alternative to the 110 year old Tuberculin Skin Test (TST), also known as the Mantoux, QFT offers unmatched specificity, high sensitivity and simplicity. QFT enables focused TB therapy by providing clinicians with an accurate, reliable and convenient TB diagnostic tool. QFT is unaffected by previous BCG vaccination and most other environmental mycobacteria. Unlike the TST, it requires only one patient visit, is a controlled laboratory test and provides an objective, reproducible result that is unaffected by subjective interpretation. Results can be available within 24 hours. QFT® is available for use in all clinical settings in which TST is commonly used. Examples include contact tracing, regular employee testing, for example for health care workers, as well as screening programs for prisoners and immigrants. QFT's application in the screening of immunosuppressed patients prior to anti-TNF-alpha therapy initiation and in patients with HIV, cancer or organ transplants offers distinct advantages over the TST. QFT® is sold directly in the U.S. by Cellestis Inc; in Europe by Cellestis GmbH (Germany); and in Australia and Asia by Cellestis International Pty. Ltd. (Australia). QFT is also available through Cellestis Commercial Partners in Japan, Europe, the Middle East and other countries around the world. About Cellestis Limited Cellestis Limited, a listed Australian biotechnology company founded in 2000 in Melbourne, Australia, develops and manufactures the QuantiFERON-TB Gold In-Tube (QFT) test, a breakthrough blood test for the detection and control of tuberculosis. The QuantiFERON technology is a patented method for detecting cell mediated immune (CMI) responses of T-cell lymphocytes using whole blood samples. In comparison to existing methods of measuring CMI, this unique technology provides accuracy and sensitivity along with major savings in operator time, labor and reagents. Using its patented QuantiFERON technology, Cellestis develops diagnostics tests that measure immune function for diseases with an unmet medical need. Cellestis is proud to be exploring opportunities to enhance the global effort to eliminate TB. Cellestis is an industry partner of FIND (the Foundation for Innovative New Diagnostics) and the Stop-TB Partnership. For more information, please visit www.cellestis.com. SOURCE Cellestis Limited http://www.earthtimes.org/articles/show/bl...s,1235190.shtml
  10. http://www.fiercebiotech.com/press-release...source=internal
  11. http://timesofindia.indiatimes.com/city/ka...how/5691545.cms
  12. Task Order #18: Evaluation of New Interferon-γ Release Assays in the Diagnosis of Latent Tuberculosis Infection in Health Care Workers This study will evaluate the test characteristics, feasibility, and cost-effectiveness of interferon-γ release assays (IGRAs) and the tuberculin skin test (TST) when testing for LTBI in health care workers (HCWs). HCWs make up a critical study population for IGRAs. According to the U.S. Department of Labor, there are approximately 14 million HCWs in the U.S., most of whom undergo serial skin testing. Testing HCWs is costly and time consuming, but detection of new infection is necessary for discovering TB transmission and for preventing occupation-related TB. The aims of the study include, but are not limited to, comparing the test characteristics (estimated sensitivity and specificity) of two IGRAs (QuantiFERON TB Gold [QFT-G] and T-Spot) to each other and to the TST at initial testing, determining the repeatability and reproducibility of the IGRA results, determining if the TST boosts the IGRA results, and comparing the cost-effectiveness of the three methods. Methods: This study involves HCWs from Denver Health and Hospital Authority. Participants are administered a questionnaire, have a TST placed and read, and have blood drawn for the IGRAs at baseline and at 6, 12, and 18-months after baseline. Enrollment began in February 2008 and was completed in January 2009. Task Order #20: Assessing QuantiFERON® as an Initial Screening Tool for U.S.-Bound Applicants for Immigration and Feasibility of Follow-Up in U.S. Immigrants This study is a collaborate effort between the Centers for Disease Control (CDC), Cho Ray Hospital (CRH) in Ho Chi Minh City, Vietnam, and The Methodist Hospital Research Institute (TMHRI) in Houston, Texas. This is a 3 phase study to look at the feasibility of conducting a larger study to examine the accuracy of the QuantiFERON-TB Gold (QFT) in predicting the future development of active TB among immigrants after arrival in the U.S. Phase 1 will evaluate the potential role of the QFT and/or the tuberculin skin test (TST) in the screening process of immigration applicants. Phase 1 will enroll 1500 individuals, including 100 people with an abnormal chest radiograph (CXR) and 500 with a normal CXR. Phase 2 will follow 120 individuals from Phase 1 to determine the feasibility of following Vietnamese immigrants moving from Vietnam to the U.S. Phase 3 is to determine the feasibility of locating and interviewing individuals who have emigrated from Vietnam and are diagnosed with TB in the U.S. For Phase 3, 25 individuals diagnosed in Colorado and Texas will be enrolled. Enrollment in this study began in December 2008. http://denverhealth.org/portal/Services/Pu...c/Research.aspx
  13. http://porterhospitallab.org/QuantiferonGo...UARY%202010.pdf
  14. http://7thspace.com/headlines/335802/diffe...s_analysis.html
  15. http://news.smh.com.au/breaking-news-world...00222-opuq.html
  16. Latent Tuberculosis Diagnosis in Children by Using the QuantiFERON-TB Gold In-Tube Test
  17. Within-Subject Variability of Interferon-g Assay Results for Tuberculosis and Boosting Effect of Tuberculin Skin Testing: A Systematic Review http://www.plosone.org/article/info:doi%2F...al.pone.0008517 "........While IGRAs have emerged as promising alternatives to the TST, there is still controversy regarding the most effective strategy for their use. For example, some national guidelines recommend replacement of the TST with the IGRA. Some recommend that either TST or IGRA can be used (but not both), while several countries (e.g. Canada, UK, Italy, Germany, Switzerland, Netherlands, Korea and Norway) recommend a two-step approach of TST first, followed by an IGRA. In fact, a recent survey of global IGRA guidelines showed that the two-step approach appears to be the most favoured guideline recommendation worldwide. [30] Boosting, clearly, is a key concern with the two-step approach, and thus far, only the Canadian guideline has explicitly addressed this issue and recommended that blood be drawn for IGRA on or before the day when the TST is read [8]. ........................Thus, it does appear that the optimal time to collect blood for IGRA is at the time of reading the TST. This approach has already been recommended in the Canadian guidelines[8]; other guidelines may need to be updated accordingly....."
  18. hey adder, just why were you searching for penis patents????
  19. http://www.watchdogsblog.com/blog/_archive...28/4414669.html
  20. http://clinicaltrialsfeeds.org/clinical-tr...how/NCT01038830
  21. http://www.informaworld.com/smpp/content~c...ll~jumptype=rss
  22. http://www.nice.org.uk/getinvolved/joinnwc...tsUpdateGDG.jsp
  23. interesting to see cst included here: http://www.researchandmarkets.com/reports/..._investment.htm
  24. http://www.news.com.au/national/mum-wants-...r-1225806808289
  25. Evaluation of the tuberculin skin test and the interferon-gamma release assay for TB screening in French healthcare workers
  • Create New...